

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5900948

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
INFINITY PHARMACEUTICALS, INC.	01/08/2020

**RECEIVING PARTY DATA**

<b>Name:</b>	ROYALTY SECURITY, LLC
<b>Street Address:</b>	1209 ORANGE STREET
<b>Internal Address:</b>	THE CORPORATION TRUST COMPANY
<b>City:</b>	WILMINGTON
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19801

**PROPERTY NUMBERS Total: 56**

Property Type	Number
Application Number:	60605020
Application Number:	60617170
Application Number:	60625676
Application Number:	60683169
Patent Number:	7230004
Patent Number:	7407967
Patent Number:	7875628
Patent Number:	8236956
PCT Number:	US2005030406
Application Number:	60878018
Application Number:	60941596
Patent Number:	7812164
Patent Number:	8785635
Patent Number:	8669365
Patent Number:	9492435
Patent Number:	9951083
Patent Number:	10406139
Application Number:	16521447
PCT Number:	US2007088990

PATENT

<b>Property Type</b>	<b>Number</b>
Patent Number:	8017648
Application Number:	13090694
Patent Number:	8227509
Patent Number:	8895576
Application Number:	13475510
Patent Number:	9145422
Patent Number:	9669011
Patent Number:	10045970
Patent Number:	10314827
Patent Number:	7964590
Patent Number:	8293760
Patent Number:	8431566
PCT Number:	US2008056229
Application Number:	60893595
Patent Number:	7648994
Patent Number:	7994191
Patent Number:	8426436
PCT Number:	US2008003200
Application Number:	61017162
Patent Number:	8716479
Patent Number:	9238672
Application Number:	61231439
Patent Number:	8703448
Application Number:	14257658
PCT Number:	US2010044597
Application Number:	61382642
Patent Number:	9394313
Patent Number:	9376447
Patent Number:	9879025
PCT Number:	US2011051553
Application Number:	16118338
PCT Number:	US2009049372
Application Number:	61362541
Application Number:	61471085
Application Number:	61492594
Application Number:	13179438
Application Number:	14455760

**CORRESPONDENCE DATA****Fax Number:** (949)475-4754*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 949-451-3800**Email:** skann@gibsondunn.com**Correspondent Name:** STEPHANIE KANN**Address Line 1:** 3161 MICHELSON DRIVE**Address Line 2:** GIBSON, DUNN & CRUTCHER LLP**Address Line 4:** IRVINE, CALIFORNIA 92612

<b>ATTORNEY DOCKET NUMBER:</b>	12702-00036
<b>NAME OF SUBMITTER:</b>	STEPHANIE KANN
<b>SIGNATURE:</b>	/stephanie kann/
<b>DATE SIGNED:</b>	01/08/2020

**Total Attachments: 18**

source=Patent Assignment (execution)Infinity#page1.tif  
source=Patent Assignment (execution)Infinity#page2.tif  
source=Patent Assignment (execution)Infinity#page3.tif  
source=Patent Assignment (execution)Infinity#page4.tif  
source=Patent Assignment (execution)Infinity#page5.tif  
source=Patent Assignment (execution)Infinity#page6.tif  
source=Patent Assignment (execution)Infinity#page7.tif  
source=Patent Assignment (execution)Infinity#page8.tif  
source=Patent Assignment (execution)Infinity#page9.tif  
source=Patent Assignment (execution)Infinity#page10.tif  
source=Patent Assignment (execution)Infinity#page11.tif  
source=Patent Assignment (execution)Infinity#page12.tif  
source=Patent Assignment (execution)Infinity#page13.tif  
source=Patent Assignment (execution)Infinity#page14.tif  
source=Patent Assignment (execution)Infinity#page15.tif  
source=Patent Assignment (execution)Infinity#page16.tif  
source=Patent Assignment (execution)Infinity#page17.tif  
source=Patent Assignment (execution)Infinity#page18.tif

## PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Assignment") is dated as of January 8, 2020 (the "Effective Date"), by and between:

(A) Infinity Pharmaceuticals, Inc., incorporated in Delaware, with registered address at The Corporation Trust Company, 1209 Orange Street, Wilmington, DE 19801, U.S.A., ("Assignor"); and

(B) Royalty Security, LLC, formed in Delaware, with registered address at The Corporation Trust Company, 1209 Orange Street, Wilmington, DE 19801, U.S.A. ("Assignee").

Assignor and Assignee shall be jointly referred to as the "Parties" and each shall be referred to individually as a "Party".

WHEREAS, Assignor holds certain right, title and interest in and to the patents and patent applications set forth on Exhibit A attached hereto and incorporated herein by reference (the "Assigned Patents");

WHEREAS, Assignor and Assignee are parties to that certain Funding Agreement, dated as of January 8, 2020 (the "Funding Agreement"), pursuant to which Assignor sold, assigned, transferred, conveyed and delivered to Assignee all of Assignor's right, title and other interests in and to certain of the assets of Assignor, including the Assigned Patents; and

WHEREAS, the execution and delivery of this Assignment is a condition to the consummation of the transaction made pursuant to the Funding Agreement.

NOW, THEREFORE, in consideration of the premises set forth above and in the Funding Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and subject to the terms and conditions set forth in the Funding Agreement:

1. Assignor does hereby irrevocably sell, assign, transfer, convey and deliver unto Assignee and its successors, assigns and legal representatives Assignor's entire right, title and interest in and to the Assigned Patents, all rights, claims and privileges of any kind related to the Assigned Patents throughout the world, including without limitation, the right to apply for registration in foreign countries with full benefit of such priority as may now or hereafter be granted to it by law, treaty or other international convention, and all rights, interests, claims and demands recoverable in law or equity, that Assignor has or may have in profits and damages for past, present and future infringements or other violations of the Assigned Patents, including, without limitation, the right to compromise, sue for and collect such profits and damages, all of the foregoing to be held and enjoyed by Assignee, its successors and assigns or their legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

2. Assignor hereby acknowledges and agrees that from and after the date hereof, Assignee shall be the exclusive owner of all of Assignor's right, title and interest in and to the Assigned Patents.

3. Assignor hereby authorizes and requests any official throughout the world whose duty it is to register and record ownership in patents, and applications, and title thereto to record Assignee as the owner of any and all rights in and to the Assigned Patents.

4. Assignor shall, at Assignee's reasonable written request and at Assignee's expense, use its commercially reasonable efforts to execute and deliver such additional documents and instruments, and to take, or refrain from taking, such other actions, as may be reasonably required to perfect Assignee's title in and to the Assigned Patents.

5. This Assignment shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to the conflict of laws rules thereof.

6. This Assignment may be executed electronically or otherwise (where permitted in an applicable jurisdiction) in any number of identical counterparts each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

*[SIGNATURE PAGE FOLLOWS]*

IN WITNESS WHEREOF, Assignor and Assignee have executed and delivered this Patent Assignment by their duly authorized representatives as of the Effective Date.

**ASSIGNOR:**

Infinity Pharmaceuticals, Inc.

By: Adelene Q. Perkins

Name: Adelene Q. Perkins  
Title: Chief Executive Officer

**ASSIGNEE:**

Royalty Security, LLC

By: \_\_\_\_\_

Name:  
Title:

[Signature Page to Patent Assignment]

**IN WITNESS WHEREOF**, Assignor and Assignee have executed and delivered this Patent Assignment by their duly authorized representatives as of the Effective Date.

**ASSIGNOR:**

Infinity Pharmaceuticals, Inc.


By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

**ASSIGNEE:**

Royalty Security, LLC

By:  \_\_\_\_\_

Name: Spike Loy \_\_\_\_\_

Title: President \_\_\_\_\_

**Exhibit A**

**Assigned Patents**

See attached



MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0027/8001	03001 P1	US	COMPLETED-INACTIVE	60/605,020	8/27/2004					INFINITY*	CYCLOPAMINE ANALOGS AND USES THEREOF
090586-0028/8001.US00	03001 P2	US	COMPLETED-INACTIVE	60/617,170	10/8/2004					INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0029/8001.US01	03001 P3	US	COMPLETED-INACTIVE	60/625,676	11/5/2004					INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0030/8001.US02	03001 P4	US	COMPLETED-INACTIVE	60/683,169	5/19/2005					INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0031/8001.US03	03001 US1	US	ISSUED	11/213,534	8/26/2005	US 2006-0074030	4/6/2006	7,230,004	6/12/2007	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0032/8001.US04	03001 US2	US	ISSUED	11/737,095	4/18/2007	US 2007-0191410	8/16/2007	7,407,967	8/5/2008	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0033/8001.US05	03001 US3	US	ISSUED	12/171,208	7/10/2008	US 2008-0269272	10/30/2008	7,875,628	1/25/2011	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0034/8001.US06	03001 US4	US	ISSUED	12/969,024	12/15/2010	US 2011-0166353	07-07-2011	8,236,956	8/7/2012	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0035/8001.AU00	03001 AU1	AU	ISSUED	2005280112	8/26/2005			2005280112	11/1/2012	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0036/8001.BR00	03001 BR1	BR	PENDING	PI0514444-2	8/26/2005					INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0037/8001.CA00	03001 CA1	CA	ISSUED	2579078	8/26/2005			2579078	11/22/2016	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0257/8001.CH00	03001 CH1	CH	ISSUED	05791140.6	8/26/2005	1817308	8/15/2007	1817308	10/8/2014	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0294/8001.CH02	03001 CH2	CH	ISSUED	10012704.2	8/26/2005	2316832	5/4/2011	2316832	3/8/2017	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0038/8001.CN00	03001 CN1	CN	ISSUED	200580035365.7	8/26/2005			ZL200580035365.7	6/8/2011	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0039/8001.CN01	03001 CN2	CN	ISSUED	201110094391.4	8/26/2005	CN 102241727A	11/16/2011	ZL201110094391.4	3/25/2015	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0255/8001.DE00	03001 DE1	DE	ISSUED	05791140.6	8/26/2005	1817308	8/15/2007	1817308	10/8/2014	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0321/8001.DE01	03001 DE3	DE	ISSUED	10012704.2	8/26/2005	2316832	5/4/2011	2316832	3/8/2017	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0290/8001.DE02	03001 DE2	DE	ISSUED	10012778.6	8/26/2005	2316833	5/4/2011	2316833	3/30/2016	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0040/8001.EP00	03001 EP1	EP	ISSUED	05791140.6	8/26/2005	1817308	8/15/2007	1817308	10/8/2014	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0041/8001.EP01	3001 EP3	EP	ISSUED	10012704.2	8/26/2005	2316832	5/4/2011	2316832	3/8/2017	INFINITY*	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF

**PATENT**

\*"Infinity" refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0042/8001.EP02	03001 EP2	EP	ISSUED	10012778.6	8/26/2005	2316833	5/4/2011	2316833	3/30/2016	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0293/8001.ES02	03001 ES2	ES	ISSUED	10012778.6	8/26/2005	2316833	5/4/2011	2316833	3/30/2016	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0254/8001.FR00	03001 FR1	FR	ISSUED	05791140.6	8/26/2005	1817308	8/15/2007	1817308	10/8/2014	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0322/8001.FR01	03001 FR3	FR	ISSUED	10012704.2	8/26/2005	2316832	5/4/2011	2316832	3/8/2017	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0289/8001.FR02	03001 FR2	FR	ISSUED	10012778.6	8/26/2005	2316833	5/4/2011	2316833	3/30/2016	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0258/8001.GB00	03001 GB1	GB	ISSUED	05791140.6	8/26/2005	1817308	8/15/2007	1817308	10/8/2014	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0319/8001.GB01	03001 GB3	GB	ISSUED	10012704.2	8/26/2005	2316832	5/4/2011	2316832	3/8/2017	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0295/8001.GB02	03001 GB2	GB	ISSUED	10012778.6	8/26/2005	2316833	5/4/2011	2316833	3/30/2016	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0043/8001.HK00	03001 HK1	HK	ABANDONED	08101580.6	8/26/2005			HK1112619	8/21/2015	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0044/8001.HK01	03001 HK2	HK	ABANDONED	11111953.9	8/26/2005	1157758A	7/6/2012			INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0045/8001.HK02	03001 HK3	HK	ISSUED	11111952.0	8/26/2005	1157757A	7/6/2012	HK1157757	6/30/2017	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0256/8001.IE00	03001 IE1	IE	ISSUED	05791140.6	8/26/2005	1817308	8/15/2007	1817308	10/8/2014	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0323/8001.IE01	03001 IE3	IE	ISSUED	10012704.2	8/26/2005	2316832	5/4/2011	2316832	3/8/2017	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0291/8001.IE02	03001 IE2	IE	ISSUED	10012778.6	8/26/2005	2316833	5/4/2011	2316833	3/30/2016	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0046/8001.II00	03001 II1	IL	ISSUED	181301	8/26/2005	181301		181301	1/30/2016	INFINITY*	CYCLOPAMINE ANALOGUES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF
090586-0047/8001.IN00	03001 IN1	IN	ISSUED	744/KOLNP/2007	8/26/2005	262780		262780	9/12/2014	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0048/8001.IN01	03001 IN2	IN	ABANDONED	364/KOLNP/2012	8/26/2005					INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0292/8001.IT02	03001 IT2	IT	ISSUED	10012778.6	8/26/2005	2316833	5/4/2011	2316833	3/30/2016	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0049/8001.JP00	03001 JP1	JP	ISSUED	2007-530162	8/26/2005	2008-511635 A	4/17/2008	5204486	2/22/2013	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0050/8001.JP01	03001 JP2	JP	ABANDONED	2012-164081	8/26/2005					INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF
090586-0051/8001.KR00	03001 KR1	KR	ISSUED	10-2007-7006979	8/26/2005			10-1487481	1/22/2015	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS USE THEREOF

PATENT

\*"Infinity" refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0052/8001.MX00	03001.MX1	MX	ISSUED	MX/02007/002342	8/26/2005			287139	6/1/2011	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0053/8001.N000	03001.N01	NO	ISSUED	2007/1264	8/26/2005			341137	8/28/2017	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0054/8001.PH00	03001.PH1	PH	ABANDONED	1-2007-500386	8/26/2005			1-2007-500386	5/31/2013	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0055/8001.RU00	03001.RU1	RU	ABANDONED	2007111126	8/26/2005			2403256	11/10/2010	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0056/8001.WO00	03001.WO1	WO	NAT PHASE COMPLETED-	PCT/US2005/030406	8/26/2005	WO2006/026430	3/9/2006			INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0057/8001.ZA00	03001.ZA1	ZA	ABANDONED	2007/01535	8/26/2005			2007/01535	12/31/2008	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0058/8002	03002A.P1	US	COMPLETED-INACTIVE	60/878,018	12/28/2006					INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0059/8002.US00	03002A.P2	US	COMPLETED-INACTIVE	60/941,596	6/1/2007					INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0060/8002.US01	03002A.US1	US	ISSUED	11/965,688	12/27/2007	US 2008-0293754	11/27/2008	7,812,164	10/12/2010	INFINITY*	CYCLOPAMINE ANALOGS
090586-0061/8002.US02	03002A.US2	US	ISSUED	12/199,689	8/27/2008	US 2009-0012109	1/8/2009	8,785,635	7/22/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0062/8002.US03	03002A.US3	US	ISSUED	12/199,722	8/27/2008	US 2009-0216022	8/27/2009	8,669,365	3/11/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0063/8002.US04	03002A.US4	US	ISSUED	14/203,297	3/10/2014	US 2014-0371253	12/18/2014	9,492,435	11/15/2016	INFINITY*	CYCLOPAMINE ANALOGS
090586-0297/8002.US05	03002A.US5	US	ISSUED	15/289,887	10/10/2016	US 2017-0022212	1/26/2017	9,951,083	4/24/2018	INFINITY*	CYCLOPAMINE ANALOGS
090586-0351/8002.US7	03002A.US7	US	PENDING	16/521,447	7/24/2019			10,406,139	9/10/2019	INFINITY*	CYCLOPAMINE ANALOGS
090586-0064/8002.AE00	03002A.AE1	AE	PENDING	600/2009	12/27/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0065/8002.AR00	03002A.AR1	AR	PENDING	070105973	12/28/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0234/8002.AT00	03002A.AT1	AT	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0066/8002.AU00	03002A.AU1	AU	ISSUED	2007339782	12/27/2007			2007339782	9/4/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0235/8002.BE00	03002A.BE1	BE	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0067/8002.BR00	03002A.BR1	BR	PENDING	PI0720972.0	12/27/2007					INFINITY*	CYCLOPAMINE ANALOGS

**PATENT**

\*Infinity refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

NME Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication Date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0068/8002.CA00	03002A CA1	CA	ISSUED	2673995	12/27/2007			2673995	6/7/2016	INFINITY*	CYCLOPAMINE ANALOGS
090586-0250/8002.CH00	03002A CH1	CH	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0069/8002.CL00	03002A CL1	CL	ISSUED	2007-3854	12/28/2007	2007-3854	5/30/2008	5161	9/23/2015	INFINITY*	CYCLOPAMINE ANALOGS
090586-0070/8002.CN00	03002A CN1	CN	ISSUED	200780051114.7	12/27/2007	CN 101631463A	1/20/2010	ZL2007800511	4/2/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0071/8002.CN01	03002A CN2	CN	ABANDONED	201410074976.3	12/27/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0236/8002.CZ00	03002A CZ1	CZ	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0240/8002.DE00	03002A DE1	DE	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0237/8002.DK00	03002A DK1	DK	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0072/8002.EP00	03002A EP1	EP	ISSUED	07870001.0	12/27/2007	2096917	9/9/2009	2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0073/8002.EP01	03002A EP2	EP	ABANDONED	11189894.6	12/27/2007	2443926	5/9/2012			INFINITY*	CYCLOPAMINE ANALOGS
090586-0074/8002.EP02	03002A EP3	EP	CLOSED							INFINITY*	CYCLOPAMINE ANALOGS
090586-0248/8002.ES00	03002A ES1	ES	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0238/8002.FI00	03002A FI1	FI	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0239/8002.FR00	03002A FR1	FR	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0251/8002.GB00	03002A GB1	GB	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0075/8002.GC00	03002A GC1	GC	ALLOWED	2007/9866	12/29/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0076/8002.HK00	03002A HK1	HK	ISSUED	10102383.9	12/27/2007	1134222	4/23/2010	HK1134222	1/23/2015	INFINITY*	CYCLOPAMINE ANALOGS
090586-0077/8002.HK01	03002A HK2	HK	ABANDONED	12110615.0	12/27/2007	1170117	2/22/2013			INFINITY*	CYCLOPAMINE ANALOGS
090586-0241/8002.HU00	03002A HU1	HU	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0078/8002.ID00	03002A ID1	ID	ISSUED	W00 2009 011773	12/27/2007			W002009011773	9/26/2017	INFINITY*	CYCLOPAMINE ANALOGS
090586-242/8002.IE00	03002A IE1	IE	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS

\*Infinity refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

PATENT

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0079/8002.LI00	03002A.LI1	IL	ISSUED	199554	12/27/2007			199554	3/1/2019	INFINITY*	CYCLOPAMINE ANALOGS AND PROCESSES FOR PRODUCING THE SAME
090586-0080/8002.IN00	03002A.IN1	IN	ISSUED	2545/KOLNP/2009	12/27/2007			268493	8/31/2015	INFINITY*	CYCLOPAMINE ANALOGS
090586-0081/8002.IQ00	03002A.IQ1	IQ	ABANDONED	251/2007	12/26/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0243/8002.IT00	03002A.IT1	IT	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0082/8002.JO00	03002A.JO1	JO	ISSUED	564/2007	12/27/2007			2947	6/28/2016	INFINITY*	CYCLOPAMINE ANALOGS
090586-0083/8002.JP00	03002A.JP1	JP	ISSUED	2009-544276	12/27/2007	2010-514796 A	5/6/2010	5412292	11/15/2013	INFINITY*	CYCLOPAMINE ANALOGS
090586-0084/8002.KR00	03002A.KR1	KR	ISSUED	10-2009-7015913	12/27/2007			10-1489394	1/28/2015	INFINITY*	CYCLOPAMINE ANALOGS
090586-0085/8002.LB00	03002A.LB1	LB	ISSUED	8020	12/28/2007			8141	2/2/2009	INFINITY*	CYCLOPAMINE ANALOGS
090586-0244/8002.LU00	03002A.LU1	LU	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0086/8002.MX00	03002A.MX1	MX	ISSUED	MX/a/2009/007077	12/27/2007			303943	10/2/2012	INFINITY*	CYCLOPAMINE ANALOGS
090586-0087/8002.MX01	03002A.MX2	MX	ISSUED	MX/a/2012/007856	12/27/2007			342683	10/7/2016	INFINITY*	CYCLOPAMINE ANALOGS
090586-0088/8002.NO00	03002A.NO1	NO	ISSUED	20092710	12/27/2007			343748	5/27/2019	INFINITY*	CYCLOPAMINE ANALOGS
090586-0341/8002.NO01	03002A.NO2	NO	PENDING	20190059	12/27/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0245/8002.NI00	03002A.NI1	NI	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0089/8002.NZ00	03002A.NZ1	NZ	ISSUED	577916	12/27/2007			577916	3/1/2013	INFINITY*	CYCLOPAMINE ANALOGS
090586-0090/8002.PE00	03002A.PE1	PE	ISSUED	000074-2008	1/2/2008			7186	7/10/2014	INFINITY*	CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF
090586-0091/8002.PH01	03002A.PH1	PH	ISSUED	1-2009-501298	12/27/2007	1-2009-501298	7/10/2008	1-2009-501298	12/12/2013	INFINITY*	CYCLOPAMINE ANALOGS
090586-0092/8002.PK00	03002A.PK1	PK	PENDING	1550/2007	12/27/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0246/8002.PL00	03002A.PL1	PL	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0247/8002.PT00	03002A.PT1	PT	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0093/8002.RU00	03002A.RU1	RU	ISSUED	2009128997	12/27/2007			2486194	6/27/2013	INFINITY*	CYCLOPAMINE ANALOGS

PATENT

\*"Infinity" refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication Date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0249/8002.SE00	03002A SE1	SE	ISSUED	07870001.0	12/27/2007			2096917	5/7/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0094/8002.SG00	03002A SG1	SG	ISSUED	200904374.6	12/27/2007			153571	2/29/2012	INFINITY*	CYCLOPAMINE ANALOGS
090586-0099/8002.SG01	03002A SG2	SG	ABANDONED	201109566.6	12/27/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0096/8002.TH00	03002A TH1	TH	PENDING	0701006724	12/26/2007	102725	7/29/2010			INFINITY*	CYCLOPAMINE ANALOGS
090586-0097/8002.TW00	03002A TW1	TW	ISSUED	096149773	12/24/2007			1433674	4/10/2014	INFINITY*	CYCLOPAMINE ANALOGS
090586-0099/8002.UA00	03002A UA1	UA	ISSUED	200907837	12/27/2007			97130	1/10/2012	INFINITY*	CYCLOPAMINE ANALOGS
090586-0099/8002.VE00	03002A VE1	VE	ABANDONED	02946.2007	12/28/2007					INFINITY*	CYCLOPAMINE ANALOGS
090586-0100/8002.WO00	03002A WO1	WO	NAT PHASE	PCT/US2007/088990	12/27/2007	WO2008/083248	7/10/2008			INFINITY*	CYCLOPAMINE ANALOGS
090586-0101/8002.ZA00	03002A ZA1	ZA	ISSUED	2009/04445	12/27/2007			2009/04445	12/29/2010	INFINITY*	CYCLOPAMINE ANALOGS
090586-0102/8003	03002B US1	US	ISSUED	11/965,675	12/27/2007	2010-0286180	11/11/2010	8,017,648	9/13/2011	INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0103/8003.US00	03002B US2	US	ABANDONED	13/090,694	4/20/2011	2011-0230509	9/22/2011			INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0104/8003.US01	03002B US3	US	ISSUED	13/191,545	7/27/2011	2012-0077834	3/29/2012	8,227,509	7/24/2012	INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0105/8003.US02	03002B US4	US	ISSUED	13/475,352	5/18/2012	2013-0108582	5/2/2013	8,895,576	11/25/2014	INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0106/8003.US03	03002B US5	US	ABANDONED	13/475,510	5/18/2012	2013-0108583	5/2/2013			INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0107/8003.US04	03002B US6	US	ISSUED	14/054,350	10/15/2013	2014-0107142	4/17/2014	9,145,422	9/29/2015	INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0266/8003.US05	03002B US7	US	ISSUED	14/841,001	8/31/2015	2016-0158208	6/9/2016	9,669,011	6/6/2017	INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0318/8003.US06	03002B US8	US	ISSUED	15/585,038	5/2/2017	2017-0360763	12/21/2017	10,045,970	8/14/2018	INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0333/8003.US07	03002B US9	US	ISSUED	16/047,008	7/27/2018	2018-0338962	11/29/2018	10,314,827	6/11/2019	INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0350/8003.US08	03002B US10	US	PENDING	16/396,565	4/26/2019					INFINITY*	METHODS OF USE OF CYCLOPAMINE ANALOGS
090586-0106/8003.AE00	3002B AE1	AE	PENDING	599/2009	12/27/2007					INFINITY*	METHODS OF USE FOR CYCLOPAMINE ANALOGS
090586-0140/8004	03005 P1	US	COMPLETED-INACTIVE	60/893,591	3/7/2007					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF

\*Infinity refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

PATENT

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0141/8004.US00	03005 US1	US	ABANDONED	12/044,878	3/7/2008			7,964,590	6/21/2011	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0142/8004.US01	03005 US2	US	ABANDONED	13/102,395	5/6/2011			8,293,760	10/23/2012	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0143/8004.US02	03005 US3	US	ABANDONED	13/250,080	9/30/2011			8,431,566	4/30/2013	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0144/8004.AU00	03005 AU1	AU	ABANDONED	2008222655	3/7/2008			2008222655	4/30/2014	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0145/8004.BR00	03005 BR1	BR	ABANDONED	P10808444-0	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0220/8004.CA00	03005 CA1	CA	ABANDONED	2679845	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0146/8004.CN00	03005 CN1	CN	ABANDONED	200880012481.0	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0146/8004.DE00	03005 DE1	DE	ABANDONED	60 2008 026 065.8	3/7/2008			2134719	7/17/2013	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0146/8004.EP00	03005 EP1	EP	ABANDONED	08731680.8	3/7/2008			2134719	7/17/2013	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0150/8004.FR00	03005 FR1	FR	ABANDONED	08731680.8	3/7/2008			2134719	7/17/2013	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0151/8004.GB00	03005 GB1	GB	ABANDONED	08731680.8	3/7/2008			2134719	7/17/2013	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0152/8004.HK00	03005 HK1	HK	ABANDONED	10106043.2	3/7/2008			HK1139930	12/13/2013	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0153/8004.IE00	03005 IE1	IE	ABANDONED	08731680.8	3/7/2008			2134719	7/17/2013	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0154/8004.IL00	03005 IL1	IL	ABANDONED	200746	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0155/8004.IN00	03005 IN1	IN	ABANDONED	3128/KOLNP/2009	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0156/8004.JP00	03005 JP1	JP	ABANDONED	2009-552909	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0157/8004.KR00	03005 KR1	KR	ABANDONED	7020902/2009	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0158/8004.MX00	03005 MX1	MX	ABANDONED	MX/9/2009/009429	3/7/2008			292496	11/23/2011	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0159/8004.NZ00	03005 NZ1	NZ	ABANDONED	579356	3/7/2008			579356	8/6/2012	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0160/8004.PH00	03005 PH1	PH	ABANDONED	1-2009-501692	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0161/8004.RU00	03005 RU1	RU	ABANDONED	2009137012	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF

**PATENT**

\*Infinity refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

NME Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0167/8004.S.G00	03006 SGI	SG	ABANDONED	200905912.2	3/7/2008			155358	4/13/2012	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0163/8004.W.O00	03005 WO1	WO	NAT-PHASE	PCT/US2008/056229	3/7/2008					INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0164/8004.Z.A00	03005 ZAI	ZA	ABANDONED	2009/06083	3/7/2008			2009/06083	3/30/2011	INFINITY*	CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF
090586-0165/8005	03006 P1	US	COMPLETED-INACTIVE	60/893,595	3/7/2007					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0166/8005.U.S00	03006 US1	US	ABANDONED	12/044,817	3/7/2008			7,648,994	1/19/2010	INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0167/8005.U.S01	03006 US2	US	ABANDONED	12/629,382	12/2/2009			7,994,191	8/9/2011	INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0168/8005.U.S02	03006 US3	US	ABANDONED	13/168,590	6/24/2011			8,426,436	4/23/2013	INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0169/8005.A.U00	03006 AU1	AU	ABANDONED	2008223355	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0170/8005.B.R00	03006 BR1	BR	ABANDONED	P10808663.0	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0171/8005.C.A00	03006 CA1	CA	ABANDONED	2680186	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0172/8005.C.N00	03006 CN1	CN	ABANDONED	200880012734.4	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0173/8005.E.P00	03006 EP1	EP	ABANDONED	08726695.3	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0174/8005.H.K00	03006 HK1	HK	ABANDONED	10105627.8	6/8/2010					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0175/8005.I.L00	03006 IL1	IL	ABANDONED	200684	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0176/8005.I.N00	03006 IN1	IN	ABANDONED	3335/KOLNP/2009	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0177/8005.J.P00	03006 JP1	JP	ABANDONED	2009-552770	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0178/8005.K.R00	03006 KR1	KR	ABANDONED	7020903/2009	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF

**PATENT**

\*"Infinity" refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.



MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0187/8005.MX00	03006.MX1	MX	ABANDONED	MX/01/2009/009428	3/7/2008			286313	5/4/2011	INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0180/8005.NZ00	03006.NZ1	NZ	ABANDONED	579361	3/7/2008			579361	8/6/2012	INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0181/8005.PH00	03006.PH1	PH	ABANDONED	1-2009-501693	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0182/8005.RU00	03006.RU1	RU	ABANDONED	2009137014	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0183/8005.SG00	03006.SG1	SG	ABANDONED	200905915-5	3/7/2008			155359	5/31/2012	INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0184/8005.WO00	03006.WO1	WO	NAT PHASE	PCT/US2008/003200	3/7/2008					INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0185/8005.ZA00	03006.ZA1	ZA	ABANDONED	2009/06089	3/7/2008			2009/06089	2/23/2011	INFINITY*	HETEROCYCLIC CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
090586-0186/8006	03007.P1	US	COMPLETED-INACTIVE	61/017,162	12/27/2007					INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0187/8006.US90	03007.US1	US	ISSUED	12/810,600	9/15/2010	US 2011-0009442	1/13/2011	8,716,479	5/6/2014	INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0221/8006.US01	03007.US2	US	ISSUED	14/268,952	5/2/2014	US 2014-0357868	12/4/2014	9,238,672	1/19/2016	INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0188/8006.AU00	03007.AU1	AU	ABANDONED	2008345097	12/24/2008					INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0342/8006.BE01	03007.BE2	BE	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0189/8006.CA00	03007.CA1	CA	ABANDONED	2710858	12/24/2008					INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0312/8006.CH00	03007.CH1	CH	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0343/8006.CH01	03007.CH2	CH	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0190/8006.CN00	03007.CN1	CN	ABANDONED	200880123155.7	12/24/2008			ZL 200880123155.7	3/19/2014	INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0191/8006.CN01	03007.CN2	CN	ABANDONED	201410029905.1	12/24/2008					INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0308/8006.DE00	03007.DE1	DE	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREoselective REDUCTION
090586-0344/8006.DE01	03007.DE2	DE	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREoselective REDUCTION

**PATENT**

\*"Infinity" refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication Date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0192/8006.EP00	03007 EP1	EP	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0299/8006.EP01	03007 EP2	EP	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0311/8006.E500	03007 ES1	ES	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0345/8006.E501	03007 ES2	ES	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0307/8006.FR00	03007 FR1	FR	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0346/8006.FR01	03007 FR2	FR	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0313/8006.G800	03007 GB1	GB	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0347/8006.G801	03007 GB2	GB	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0193/8006.HK00	03007 HK1	HK	ABANDON	11102273.1	3/7/2011					INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0309/8006.IE00	03007 IE1	IE	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0346/8006.IE01	03007 IE2	IE	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0310/8006.IT00	03007 IT1	IT	ISSUED	08868213.3	12/24/2008	2224807	9/8/2010	2224807	11/9/2016	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0349/8006.IT01	03007 IT2	IT	ISSUED	16197797	12/24/2008	3190121	7/12/2017	3190121	2/20/2019	INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0194/8006.JP00	03007 JP1	JP	ABANDON	2010-540893	12/24/2008					INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0195/8006.WO00	03007 WO1	WO	COMPLETED	PCT/US2008/088302	12/24/2008	WO2009/086451	7/9/2009			INFINITY*	METHODS FOR STEREOSELECTIVE REDUCTION
090586-0226/8007	03011 P1		COMPLETED-INACTIVE	61/231,439	8/5/2009					INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0196/8007	03011 US1	US	ISSUED	13/175,053	7/1/2011	2012-0083607	4/5/2012	8,703,448	4/22/2014	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0197/8007.U.S00	03011 US2	US	ABANDON	14/257,658	4/21/2014	2014-0371456	12/18/2014			INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0276/8007.U.S01	03011 US3	US	ISSUED	15/054,011	2/25/2016	2016-0177354	6/23/2016	9,879,293	1/30/2018	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0227/8007.AU00	03011 AU1	AU	ISSUED	2010279325	8/5/2010			2010279325	2/2/2017	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0284/8007.BE00	03011 BE1	BE	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS

**PATENT**

\*Infinity refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0228/8007.CA00	03011 CA1	CA	ALLOWED	2769795	8/5/2010					INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0281/8007.CH00	03011 CH1	CH	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0233/8007.CN00	03011 CN1	CN	ABANDONED	201080037074.2	8/5/2010					INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0277/8007.DE00	03011 DE1	DE	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0229/8007.EP00	03011 EP1	EP	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0282/8007.ES00	03011 ES1	ES	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0278/8007.FR00	03011 FR1	FR	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0279/8007.GB00	03011 GB1	GB	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0283/8007.IE00	03011 IE1	IE	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0280/8007.IT00	03011 IT1	IT	ISSUED	10807181.2	8/5/2010	2462115	6/13/2012	2462115	1/6/2016	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0230/8007.JP00	03011 JP1	JP	ISSUED	2012-523957	8/5/2010			6141015	5/12/2017	INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0317/8007.JP01	03011 JP2	JP	ABANDONED	2017-041630	8/5/2010					INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0201/8008.WO00	03011 WO1	WO	COMPLETED-INACTIVE	PCT/US2010/044597	8/5/2010	WO2011/017551	2/10/2011			INFINITY*	ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
090586-0198/8008	03024 P1	US	COMPLETED-INACTIVE	61/382,642	9/14/2010					INFINITY*	TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS
090586-0199/8008.US00	03024 US1	US	ISSUED	13/232,851	9/14/2011	US 2012-0065399 A1	3/15/2012	9,394,313	7/19/2016	INFINITY*	TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS
090586-0202/8009	03024 US2	US	ISSUED	13/232,898	9/14/2011	US 2012-0065400 A1	3/15/2012	9,376,447	6/28/2016	INFINITY*	TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS
090586-0296/8008.US02	03024 US3	US	ISSUED	15/191,371	6/23/2016	US 2017-0029433 A1	2/2/2017	9,879,025	1/30/2018	INFINITY*	TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS
090586-0201/8008.WO00	03024 WO1	WO	NAT PHASE	PCT/US2011/051553	9/14/2011					INFINITY*	TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS
090586-0202/8009	03009 P1	US	COMPLETED-INACTIVE	61/077,703	7/2/2008					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0203/8009.US00	03009 US1	US	ABANDON	12/496,013	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0275/8009.US01	03009 US2	US	ABANDON	15/050,405	2/22/2016	US 2016-0168193 A1	6/16/2019			INFINITY*	ISOLATION OF CYCLOPAMINE

PATENT

\*Infinity refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

MWI Reference #	INFINITY Reference #	COUNTRY	STATUS	Application No.	FILING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0336/8009.US02	03009.US3	US	PENDING	16/118,338	8/30/2018	US 2019-0269852 A1	8/29/2019			INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0204/8009.AR00	03009.AR1	AR	ABANDON	P09.01.02408	6/29/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0205/8009.AU00	03009.AU1	AU	ABANDON	2009266993	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0206/8009.BR00	03009.BR1	BR	ABANDON	P10913997.4	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0207/8009.CA00	03009.CA1	CA	ABANDON	2729110	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0208/8009.CL00	03009.CL1	CL	ABANDON	1479-2009	6/24/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0209/8009.CN00	03009.CN1	CN	ABANDON	200980133777.2	7/1/2009			ZL200980133777.2	4/24/2013	INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0210/8009.EP00	03009.EP1	EP	PENDING	09774420.5	7/1/2009			2318027		INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0211/8009.HK00	03009.HK1	HK	ABANDON	11112226.8	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0212/8009.IL00	03009.IL1	IL	ABANDON	210149	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0213/8009.JP00	3009.JP1	JP	ABANDON	2011516844	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0214/8009.KR00	03009.KR1	KR	ABANDON	10-2011-7002378	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0215/8009.PE00	03009.PE1	PE	ABANDON	000912-2009/DIN	6/29/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0216/8009.TW00	03009.TW1	TW	ABANDON	098122061	6/30/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0217/8009.VE00	03009.VE1	VE	ABANDON	1224.09	6/30/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0218/8009.WO00	03009.WO1	WO	NAT PHASE	PCT/US2009/049372	7/1/2009					INFINITY*	ISOLATION OF CYCLOPAMINE
090586-0222/8010	03021.P1	US	COMPLETED-INACTIVE	61/362,541	7/8/2010					INFINITY*	METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING
090586-0223/8010.US00	03022.P1	US	COMPLETED-INACTIVE	61/362,557	7/8/2010					INFINITY*	METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING

PATENT

\*"Infinity" refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.

MWI Reference#	INFINITY Reference #	COUNTRY	STATUS	Application No.	FLING DATE	Publication No.	Publication date	PATENT #	ISSUE DATE	Assignee	TITLE
090586-0224/8010.US01	03022 P2	US	COMPLETED-INACTIVE	61/471,085	4/1/2011					INFINITY*	METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING
090586-0225/8010.US02	03022 P3	US	COMPLETED-INACTIVE	61/492,594	6/2/2011					INFINITY*	METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING
090586-0219/8010.US03	03022 US1	US	ABANDON	13/179,438	7/8/2011	2012-0010230	1/12/2012			INFINITY*	METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING
090586-0252/8010.US04	03022 US2	US	ABANDON	14/455,760	8/8/2014	2015-0025012	1/22/2015			INFINITY*	METHODS AND COMPOSITIONS FOR IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCERS ASSOCIATED WITH HEDGEHOG SIGNALING

**PATENT**

\*"Infinity" refers to either Infinity Pharmaceuticals, Inc., or Infinity Discovery, Inc., a wholly owned subsidiary of Infinity Pharmaceuticals.